Despite these limitations, our results suggest a protective role of BDNF Val66Met polymorphism against CI in MS patients, possibly reflecting a detrimental effect of increased BDNF concentration in a neuroinflammatory environment. This evidence concerns the gene BDNF and myeloid sarcoma.